Have you been diagnosed with HER2 positive (HER2+) breast cancer and have recently or plan to undergo surgery? If so, you may be able to take part in a research study looking at the safety of giving two drugs trastuzumab and pertuzumab in combination with hormonal therapy after surgery for your breast cancer.

Are you an elderly patient with locally advanced Head and Neck squamous cell carcinoma who is ineligible for standard treatment involving platinum based therapy (e.g. Carboplatin or Cisplatin)? If so, you may be eligible to participate in a clinical research study involving an investigational drug, called NBTXR3.

If you or your child had or currently have abnormal cell growth or a related condition, including brain and nervous system tumors, you may be able to take part in a research study. This is a study for patients who are receiving treatment at UNC hospitals. In this study, we will collect samples to better understand the causes of your disease.

The purpose of this study is to determine if MIRV plus Bev can help to prevent your cancer from returning or delaying your cancer's return.

Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety of giving a new drug to patients with multiple myeloma.

Have you been diagnosed with triple negative breast cancer? If so, you may be able to take part in a research study looking at the safety of giving a new drug called Sacituzumab Govitecan with or without a drug called Pembrolizumab to patients with PDL-1-negative metastatic triple negative breast cancer.

Do you have renal cell cancer that has spread beyond your kidney and surgery is not recommended? You may be able to take part in a research study to help us learn if adding radiation therapy to your usual cancer treatment may help your cancer shrink.

Are you suspected of having or have been diagnosed with ovarian cancer? if so, you may be able to participate in a research study looking at creating personalized stem cells from the skin of ovarian cancer patients to see if these stem cells can attack cancer cells. This work may be able to help us find more treatment options for ovarian cancer patients in the future.

The purpose of this research study is to see if adding the PARP inhibitor olaparib concurrently with SRS followed by immunotherapy (durvalumab) and chemotherapy will lead to better control of breast cancer that has spread to the brain better than the standard approach.

The purpose of this study is to find out if an investigational medication (NBTXR3) could help elderly patients with locally advanced head & neck squamous cell carcinoma who are otherwise ineligible to receive platinum-based chemotherapy. This study will help to determine the recommended dose/s of NBTXR3. The study medication is injected directly into the tumor and is activated by radiation therapy in combination with anti-PD1 therapy.